Related Experiment Videos
Severe hypersensitivity pneumonitis associated with anagrelide.
Murugan Raghavan1, Mark A Mazer, David J Brink
1Department of Critical Care Medicine, Conemaugh Valley Memorial Hospital, Johnstown, PA 15905, USA.
The Annals of Pharmacotherapy
|August 19, 2003
Summary
This case report details a severe hypersensitivity pneumonitis linked to anagrelide therapy in a myeloproliferative disorder patient. Prompt discontinuation and treatment led to significant recovery, highlighting a rare but serious adverse drug event.
Area of Science:
- Pulmonology
- Pharmacology
- Hematology
Background:
- Anagrelide is used to manage thrombocytosis in myeloproliferative disorders.
- Hydroxyurea is a common treatment for chronic myeloid leukemia.
- Severe pulmonary adverse events are not frequently associated with anagrelide therapy.
Observation:
- A 60-year-old woman with chronic myeloid leukemia developed severe hypersensitivity pneumonitis after starting anagrelide.
- High-resolution CT revealed extensive bilateral lung infiltrates.
- Bronchoalveolar lavage indicated a lymphocytic response, suggestive of hypersensitivity.
Findings:
- Anagrelide was identified as the probable cause of hypersensitivity pneumonitis.
- Discontinuation of anagrelide and hydroxyurea, along with corticosteroid treatment, resulted in dramatic clinical improvement.
- This is the first reported case of severe hypersensitivity pneumonitis associated with anagrelide.
Implications:
- Healthcare providers should maintain vigilance for dyspnea in patients on anagrelide and hydroxyurea.
- Awareness of this rare but life-threatening adverse drug reaction is crucial.
- Monitoring may include chest imaging, pulmonary function tests, and echocardiography.